表紙:がん対症療法製品の世界市場 - 業界動向と2028年までの予測
市場調査レポート
商品コード
977614

がん対症療法製品の世界市場 - 業界動向と2028年までの予測

Global Cancer Supportive Care Products Market - Industry Trends and Forecast to 2028

出版日: | 発行: Data Bridge Market Research Private Limited | ページ情報: 英文 416 Pages | 納期: 3-5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.72円
がん対症療法製品の世界市場 - 業界動向と2028年までの予測
出版日: 2020年11月01日
発行: Data Bridge Market Research Private Limited
ページ情報: 英文 416 Pages
納期: 3-5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のがん対症療法製品市場は、2021年~2028年の予測期間中に、CAGRで4.8%の成長が予測されています。

当レポートでは、世界のがん対症療法製品市場について調査分析し、市場概要、セグメント別の市場分析、地域別の市場分析、競合情勢、主要企業などについて、体系的な情報を提供しています。

目次

第1章 イントロダクション

第2章 市場セグメンテーション

第3章 エグゼクティブサマリー

第4章 規制

第5章 市場概要

  • 促進要因
  • 抑制要因
  • 機会
  • 課題

第6章 世界のがん対症療法製品市場に対するCOVID-19の影響

  • 価格への影響
  • サプライチェーンへの影響
  • 需要への影響
  • メーカー向け戦略的意思決定
  • 結論

第7章 世界のがん対症療法製品市場:薬剤分類別

  • 概要
  • 顆粒球コロニー刺激因子 (G-CSF)
  • エリスロポエチン刺激剤 (ESA)
  • オピオイド鎮痛薬
  • モノクローナル抗体
  • 非ステロイド性抗炎症薬 (NSAIDs)
  • ビスフォスフォネート (BP)
  • 制吐薬
  • 抗ヒスタミン薬
  • その他

第8章 世界のがん対症療法製品市場:タイプ別

  • 概要
  • ブランド
  • ジェネリック

第9章 世界のがん対症療法製品市場:がんの種類別

  • 概要
  • 肺がん
  • 乳がん
  • 前立腺がん
  • 肝臓がん
  • 膀胱がん
  • 白血病
  • 黒色腫
  • 卵巣がん
  • その他のがん

第10章 世界のがん対症療法製品市場:エンドユーザー別

  • 概要
  • 病院
  • クリニック
  • 病院・学術機関
  • その他

第11章 世界のがん対症療法製品市場:チャネル別

  • 概要
  • 病院薬局
  • 小売薬局
  • 調剤薬局

第12章 世界のがん対症療法製品市場:地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • スイス
    • オランダ
    • ロシア
    • トルコ
    • その他の欧州
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • シンガポール
    • マレーシア
    • タイ
    • インドネシア
    • フィリピン
    • その他のアジア太平洋地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • エジプト
    • その他の中東・アフリカ

第13章 世界のがん対症療法製品市場:企業情勢

  • 企業シェア分析:世界
  • 企業シェア分析:北米
  • 企業シェア分析:欧州
  • 企業シェア分析:アジア太平洋地域

第14章 SWOT分析

第15章 企業プロファイル

  • AMGEN INC.
  • PFIZER INC.
  • JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
  • NOVARTIS AG
  • ACACIA PHARMA GROUP PLC
  • ACROTECH BIOPHARMA
  • APR
  • BAXTER
  • BAYER AG
  • F. HOFFMANN-LA ROCHE LTD
  • HELSINN HEALTHCARE SA
  • HERON THERAPEUTICS, INC.
  • KYOWA KIRIN CO., LTD.
  • MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
  • MYLAN N.V.
  • OXFORD PHARMASCIENCE LTD
  • SPECTRUM PHARMACEUTICALS, INC.
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • TERSERA THERAPEUTICS LLC
  • TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)

第16章 アンケート

第17章 関連レポート

図表

LIST OF TABLES

  • TABLE 1 NEW CANCER CASES, AGES 85+, IN THE U.S.
  • TABLE 2 MORTALITY DUE TO CANCER, AGES 85+, IN THE U.S.
  • TABLE 3 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE 2020-2028 (USD MILLION)
  • TABLE 4 GLOBAL GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 5 GLOBAL GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 6 GLOBAL ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 7 GLOBAL ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 8 GLOBAL OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 9 GLOBAL OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 10 GLOBAL MONOCLONAL ANTIBODIES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 11 GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 12 GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 13 GLOBAL OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 14 GLOBAL PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 15 GLOBAL BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 16 GLOBAL BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 17 GLOBAL ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 18 GLOBAL ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 19 GLOBAL ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 20 GLOBAL ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 21 GLOBAL OTHERS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 22 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE 2020-2028 (USD MILLION)
  • TABLE 23 GLOBAL BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 24 GLOBAL BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 25 GLOBAL GENERICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 26 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2020-2028 (USD MILLION)
  • TABLE 27 GLOBAL LUNG CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 28 GLOBAL BREAST CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 29 GLOBAL PROSTATE CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 30 GLOBAL LIVER CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 31 GLOBAL BLADDER CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 32 GLOBAL LEUKAEMIA IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 33 GLOBAL MELANOMA IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 34 GLOBAL OVARIAN CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 35 GLOBAL OTHER CANCERS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 36 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2020-2028 (USD MILLION)
  • TABLE 37 GLOBAL HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 38 GLOBAL HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 39 GLOBAL CLINICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 40 GLOBAL HOSPITALS & ACADEMIC INSTITUTIONS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 41 GLOBAL OTHERS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 42 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
  • TABLE 43 GLOBAL HOSPITAL PHARMACIES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 44 GLOBAL RETAIL PHARMACIES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 45 GLOBAL COMPOUNDING PHARMACIES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 46 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 47 NORTH-AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY COUNTRY 2019-2028 (USD MILLION)
  • TABLE 48 NORTH-AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 49 NORTH-AMERICA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 50 NORTH-AMERICA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 51 NORTH-AMERICA ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 52 NORTH-AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 53 NORTH-AMERICA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 54 NORTH-AMERICA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 55 NORTH-AMERICA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 56 NORTH-AMERICA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 57 NORTH-AMERICA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 58 NORTH-AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 59 NORTH-AMERICA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 60 NORTH-AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 61 NORTH-AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 62 NORTH-AMERICA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 63 NORTH-AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 64 U.S.CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 65 U.S.GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 66 U.S.OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 67 U.S. ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 68 U.S.NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 69 U.S. OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 70 U.S. PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 71 U.S. BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 72 U.S. ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 73 U.S. ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 74 U.S. CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 75 U.S. BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 76 U.S. CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 77 U.S. CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 78 U.S. HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 79 U.S. CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 80 CANADA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 81 CANADA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 82 CANADA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 83 CANADA ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 84 CANADA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 85 CANADA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 86 CANADA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 87 CANADA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 88 CANADA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 89 CANADA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 90 CANADA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 91 CANADA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 92 CANADA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 93 CANADA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 94 CANADA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 95 CANADA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 96 MEXICO CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 97 MEXICO GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 98 MEXICO OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 99 MEXICO ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 100 MEXICO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 101 MEXICO OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 102 MEXICO PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 103 MEXICO BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 104 MEXICO ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 105 MEXICO ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 106 MEXICO CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 107 MEXICO BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 108 MEXICO CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 109 MEXICO CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 110 MEXICO HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 111 MEXICO CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 112 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY COUNTRY 2019-2028 (USD MILLION)
  • TABLE 113 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 114 EUROPE GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 115 EUROPE OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 116 EUROPE ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 117 EUROPE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 118 EUROPE OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 119 EUROPE PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 120 EUROPE BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 121 EUROPE ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 122 EUROPE ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 123 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 124 EUROPE BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 125 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 126 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 127 EUROPE HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 128 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 129 GERMANY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 130 GERMANY GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 131 GERMANY OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 132 GERMANY ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 133 GERMANY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 134 GERMANY OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 135 GERMANY PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 136 GERMANY BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 137 GERMANY ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 138 GERMANY ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 139 GERMANY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 140 GERMANY BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 141 GERMANY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 142 GERMANY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 143 GERMANY HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 144 GERMANY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 145 FRANCE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 146 FRANCE GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 147 FRANCE OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 148 FRANCE ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 149 FRANCE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 150 FRANCE OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 151 FRANCE PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 152 FRANCE BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 153 FRANCE ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 154 FRANCE ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 155 FRANCE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 156 FRANCE BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 157 FRANCE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 158 FRANCE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 159 FRANCE HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 160 FRANCE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 161 U.K CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 162 U.K GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 163 U.K OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 164 U.K ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 165 U.K NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 166 U.K OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 167 U.K PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 168 U.K BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 169 U.K ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 170 U.K ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 171 U.K CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 172 U.K BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 173 U.K CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 174 U.K CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 175 U.K HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 176 U.K CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 177 ITALY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 178 ITALY GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 179 ITALY OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 180 ITALY ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 181 ITALY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 182 ITALY OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 183 ITALY PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 184 ITALY BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 185 ITALY ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 186 ITALY ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 187 ITALY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 188 ITALY BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 189 ITALY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 190 ITALY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 191 ITALY HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 192 ITALY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 193 SPAIN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 194 SPAIN GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 195 SPAIN OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 196 SPAIN ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 197 SPAIN NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 198 SPAIN OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 199 SPAIN PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 200 SPAIN BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 201 SPAIN ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 202 SPAIN ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 203 SPAIN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 204 SPAIN BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 205 SPAIN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 206 SPAIN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 207 SPAIN HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 208 SPAIN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 209 SWITZERLAND CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE 2019-2028 (USD MILLION)
  • TABLE 210 SWITZERLAND GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 211 SWITZERLAND OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 212 SWITZERLAND ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 213 SWITZERLAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 214 SWITZERLAND OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION) (USD MILLION)
  • TABLE 215 SWITZERLAND PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 216 SWITZERLAND BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 217 SWITZERLAND ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 218 SWITZERLAND ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 219 SWITZERLAND CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 220 SWITZERLAND BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 221 SWITZERLAND CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 222 SWITZERLAND CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 223 SWITZERLAND HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 224 SWITZERLAND CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 225 NETHERLANDS CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE 2019-2028 (USD MILLION)
  • TABLE 226 NETHERLANDS GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 227 NETHERLANDS OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 228 NETHERLANDS ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 229 NETHERLANDS NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 230 NETHERLANDS OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION) (USD MILLION)
  • TABLE 231 NETHERLANDS PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 232 NETHERLANDS BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 233 NETHERLANDS ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 234 NETHERLANDS ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 235 NETHERLANDS CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 236 NETHERLANDS BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 237 NETHERLANDS CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 238 NETHERLANDS CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 239 NETHERLANDS HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 240 NETHERLANDS CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 241 RUSSIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 242 RUSSIA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 243 RUSSIA OPOID ANALGESIC IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 244 RUSSIA ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 245 RUSSIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 246 RUSSIA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 247 RUSSIA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 248 RUSSIA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 249 RUSSIA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 250 RUSSIA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 251 RUSSIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 252 RUSSIA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 253 RUSSIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 254 RUSSIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 255 RUSSIA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 256 RUSSIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 257 TURKEY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 258 TURKEY GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 259 TURKEY OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 260 TURKEY ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 261 TURKEY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 262 TURKEY OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 263 TURKEY PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 264 TURKEY BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 265 TURKEY ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 266 TURKEY ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 267 TURKEY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 268 TURKEY BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 269 TURKEY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 270 TURKEY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 271 TURKEY HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 272 TURKEY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 273 REST OF EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 274 ASIA-PACIFIC CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY COUNTRY 2019-2028 (USD MILLION)
  • TABLE 275 ASIA-PACIFIC CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028(USD MILLION)
  • TABLE 276 ASIA-PACIFIC GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 277 ASIA-PACIFIC OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 278 ASIA-PACIFIC ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 279 ASIA-PACIFIC NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 280 ASIA-PACIFIC OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 281 ASIA-PACIFIC PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 282 ASIA-PACIFIC BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 283 ASIA-PACIFIC ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 284 ASIA-PACIFIC ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 285 ASIA-PACIFIC CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 286 ASIA-PACIFIC BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 287 ASIA-PACIFIC CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 288 ASIA-PACIFIC CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 289 ASIA-PACIFIC HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 290 ASIA-PACIFIC CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 291 JAPAN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028(USD MILLION)
  • TABLE 292 JAPAN GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 293 JAPAN OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 294 JAPAN ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 295 JAPAN NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 296 JAPAN OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 297 JAPAN PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 298 JAPAN BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 299 JAPAN ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 300 JAPAN ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 301 JAPAN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 302 JAPAN BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 303 JAPAN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 304 JAPAN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 305 JAPAN HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 306 JAPAN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 307 CHINA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028(USD MILLION)
  • TABLE 308 CHINA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 309 CHINA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 310 CHINA ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 311 CHINA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 312 CHINA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 313 CHINA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 314 CHINA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 315 CHINA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 316 CHINA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 317 CHINA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 318 CHINA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 319 CHINA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 320 CHINA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 321 CHINA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 322 CHINA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 323 INDIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028(USD MILLION)
  • TABLE 324 INDIA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 325 INDIA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 326 INDIA ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 327 INDIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 328 INDIA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 329 INDIA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 330 INDIA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 331 INDIA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 332 INDIA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 333 INDIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 334 INDIA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 335 INDIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 336 INDIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 337 INDIA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 338 INDIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 339 SOUTH KOREA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028(USD MILLION)
  • TABLE 340 SOUTH KOREA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 341 SOUTH KOREA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 342 SOUTH KOREA ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 343 SOUTH KOREA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 344 SOUTH KOREA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 345 SOUTH KOREA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 346 SOUTH KOREA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 347 SOUTH KOREA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 348 SOUTH KOREA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 349 SOUTH KOREA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 350 SOUTH KOREA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 351 SOUTH KOREA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 352 SOUTH KOREA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 353 SOUTH KOREA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 354 SOUTH KOREA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 355 AUSTRALIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028(USD MILLION)
  • TABLE 356 AUSTRALIA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 357 AUSTRALIA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 358 AUSTRALIA ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 359 AUSTRALIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 360 AUSTRALIA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 361 AUSTRALIA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 362 AUSTRALIA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 363 AUSTRALIA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 364 AUSTRALIA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 365 AUSTRALIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 366 AUSTRALIA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 367 AUSTRALIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 368 AUSTRALIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 369 AUSTRALIA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 370 AUSTRALIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 371 SINGAPORE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028(USD MILLION)
  • TABLE 372 SINGAPORE GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 373 SINGAPORE OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 374 SINGAPORE ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 375 SINGAPORE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 376 SINGAPORE OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 377 SINGAPORE PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 378 SINGAPORE BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 379 SINGAPORE ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 380 SINGAPORE ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 381 SINGAPORE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 382 SINGAPORE BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 383 SINGAPORE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 384 SINGAPORE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 385 SINGAPORE HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 386 SINGAPORE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 387 MALAYSIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028(USD MILLION)
  • TABLE 388 MALAYSIA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 389 MALAYSIA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 390 MALAYSIA ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 391 MALAYSIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 392 MALAYSIA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 393 MALAYSIA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 394 MALAYSIA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 395 MALAYSIA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 396 MALAYSIA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 397 MALAYSIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 398 MALAYSIA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 399 MALAYSIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 400 MALAYSIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 401 MALAYSIA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 402 MALAYSIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 403 THAILAND CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028(USD MILLION)
  • TABLE 404 THAILAND GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 405 THAILAND OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 406 THAILAND ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 407 THAILAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 408 THAILAND OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 409 THAILAND PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 410 THAILAND BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 411 THAILAND ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 412 THAILAND ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 413 THAILAND CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 414 THAILAND BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 415 THAILAND CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 416 THAILAND CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 417 THAILAND HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 418 THAILAND CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 419 INDONESIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028(USD MILLION)
  • TABLE 420 INDONESIA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 421 INDONESIA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 422 INDONESIA ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 423 INDONESIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 424 INDONESIA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 425 INDONESIA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 426 INDONESIA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 427 INDONESIA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 428 INDONESIA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 429 INDONESIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 430 INDONESIA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 431 INDONESIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 432 INDONESIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 433 INDONESIA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 434 INDONESIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 435 PHILIPPINES CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028(USD MILLION)
  • TABLE 436 PHILIPPINES GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 437 PHILIPPINES OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 438 PHILIPPINES ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 439 PHILIPPINES NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 440 PHILIPPINES OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 441 PHILIPPINES PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 442 PHILIPPINES BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 443 PHILIPPINES ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 444 PHILIPPINES ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 445 PHILIPPINES CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 446 PHILIPPINES BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 447 PHILIPPINES CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 448 PHILIPPINES CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 449 PHILIPPINES HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 450 PHILIPPINES CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 451 REST OF ASIA-PACIFIC CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 452 SOUTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY COUNTRY 2019-2028 (USD MILLION)
  • TABLE 453 SOUTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 454 SOUTH AMERICA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 455 SOUTH AMERICA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 456 SOUTH AMERICA ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 457 SOUTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 458 SOUTH AMERICA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 459 SOUTH AMERICA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 460 SOUTH AMERICA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 461 SOUTH AMERICA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 462 SOUTH AMERICA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 463 SOUTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 464 SOUTH AMERICA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 465 SOUTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 466 SOUTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 467 SOUTH AMERICA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 468 SOUTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 469 BRAZIL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 470 BRAZIL GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 471 BRAZIL OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 472 BRAZIL ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 473 BRAZIL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 474 BRAZIL OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 475 BRAZIL PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 476 BRAZIL BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 477 BRAZIL ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 478 BRAZIL ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 479 BRAZIL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 480 BRAZIL BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 481 BRAZIL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 482 BRAZIL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 483 BRAZIL HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 484 BRAZIL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 485 ARGENTINA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 486 ARGENTINA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 487 ARGENTINA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 488 ARGENTINA ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 489 ARGENTINA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 490 ARGENTINA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 491 ARGENTINA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 492 ARGENTINA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 493 ARGENTINA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 494 ARGENTINA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 495 ARGENTINA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 496 ARGENTINA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 497 ARGENTINA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 498 ARGENTINA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 499 ARGENTINA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 500 ARGENTINA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 501 ARGENTINA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 502 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY COUNTRY 2019-2028 (USD MILLION)
  • TABLE 503 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 504 MIDDLE EAST & AFRICA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 505 MIDDLE EAST & AFRICA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 506 MIDDLE EAST & AFRICA ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 507 MIDDLE EAST & AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 508 MIDDLE EAST & AFRICA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 509 MIDDLE EAST & AFRICA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 510 MIDDLE EAST & AFRICA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 511 MIDDLE EAST & AFRICA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 512 MIDDLE EAST & AFRICA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 513 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 514 MIDDLE EAST & AFRICA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 515 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 516 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 517 MIDDLE EAST & AFRICA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 518 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 519 SOUTH AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2020 (USD MILLION)
  • TABLE 520 SOUTH AFRICA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 521 SOUTH AFRICA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 522 SOUTH AFRICA ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 523 SOUTH AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 524 SOUTH AFRICA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 525 SOUTH AFRICA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 526 SOUTH AFRICA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 527 SOUTH AFRICA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 528 SOUTH AFRICA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 529 SOUTH AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 530 SOUTH AFRICA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 531 SOUTH AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 532 SOUTH AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 533 SOUTH AFRICA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 534 SOUTH AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 535 SAUDI ARABIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2020 (USD MILLION)
  • TABLE 536 SAUDI ARABIA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 537 SAUDI ARABIA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 538 SAUDI ARABIA ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 539 SAUDI ARABIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 540 SAUDI ARABIA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 541 SAUDI ARABIA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 542 SAUDI ARABIA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 543 SAUDI ARABIA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 544 SAUDI ARABIA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 545 SAUDI ARABIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 546 SAUDI ARABIA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 547 SAUDI ARABIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 548 SAUDI ARABIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 549 SAUDI ARABIA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 550 SAUDI ARABIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 551 UAE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2020 (USD MILLION)
  • TABLE 552 UAE GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 553 UAE OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 554 UAE ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 555 UAE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 556 UAE OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 557 UAE PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 558 UAE BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 559 UAE ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 560 UAE ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 561 UAE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 562 UAE BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 563 UAE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 564 UAE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 565 UAE HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 566 UAE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 567 ISRAEL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2020 (USD MILLION)
  • TABLE 568 ISRAEL GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 569 ISRAEL OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 570 ISRAEL ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 571 ISRAEL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 572 ISRAEL OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 573 ISRAEL PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 574 ISRAEL BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 575 ISRAEL ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 576 ISRAEL ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 577 ISRAEL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 578 ISRAEL BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 579 ISRAEL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 580 ISRAEL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 581 ISRAEL HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 582 ISRAEL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 583 EGYPT CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2020 (USD MILLION)
  • TABLE 584 EGYPT GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 585 EGYPT OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 586 EGYPT ERYTHROPOIETIN STIMULATING AGENTS (ESA'S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 587 EGYPT NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 588 EGYPT OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 589 EGYPT PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 590 EGYPT BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 591 EGYPT ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 592 EGYPT ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
  • TABLE 593 EGYPT CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 594 EGYPT BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 595 EGYPT CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
  • TABLE 596 EGYPT CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 597 EGYPT HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 598 EGYPT CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 599 REST OF MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2020 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: SEGMENTATION 51
  • FIGURE 2 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: DATA TRIANGULATION 54
  • FIGURE 3 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: DROC ANALYSIS 55
  • FIGURE 4 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 56
  • FIGURE 5 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: COMPANY RESEARCH ANALYSIS 56
  • FIGURE 6 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: INTERVIEW DEMOGRAPHICS 57
  • FIGURE 7 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: DBMR MARKET POSITION GRID 59
  • FIGURE 8 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: VENDOR SHARE ANALYSIS 60
  • FIGURE 9 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: SEGMENTATION 63
  • FIGURE 10 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028 65
  • FIGURE 11 GROWING CANCER BUREN WORLDWIDE IS EXPECTED TO DRIVE THE GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028 66
  • FIGURE 12 GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET IN 2021 & 2028 66
  • FIGURE 13 ASIA-PACIFIC IS THE FASTEST GROWING REGION FOR CANCER SUPPORTIVE CARE PRODUCTS MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028 67
  • FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET 71
  • FIGURE 15 ESTIMATED NUMBER OF NEW CASES IN 2018, WORLDWIDE, BOTH SEXES, ALL AGES 72
  • FIGURE 16 ESTIMATED AGE-STANDARDIZED INCIDENCE RATES (WORLD) IN 2018, WORLDWIDE, BOTH SEXES, ALL AGES 73
  • FIGURE 17 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DRUG TYPE, 2020 87
  • FIGURE 18 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DRUG TYPE, 2020-2028 (USD MILLION) 88
  • FIGURE 19 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DRUG TYPE, CAGR (2021-2028) 88
  • FIGURE 20 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DRUG TYPE, LIFELINE CURVE 89
  • FIGURE 21 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE, 2020 106
  • FIGURE 22 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE 2020-2028 (USD MILLION) 107
  • FIGURE 23 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE, CAGR (2021-2028) 107
  • FIGURE 24 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE, LIFELINE CURVE 108
  • FIGURE 25 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY CANCER TYPE, 2020 113
  • FIGURE 26 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY CANCER TYPE, 2020-2028 (USD MILLION) 114
  • FIGURE 27 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY CANCER TYPE, CAGR (2021-2028) 114
  • FIGURE 28 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY CANCER TYPE, LIFELINE CURVE 115
  • FIGURE 29 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY END USER, 2020 123
  • FIGURE 30 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY END USER, 2020-2028 (USD MILLION) 124
  • FIGURE 31 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY END USER, CAGR (2021-2028) 124
  • FIGURE 32 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY END USER, LIFELINE CURVE 125
  • FIGURE 33 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, 2020 131
  • FIGURE 34 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION) 132
  • FIGURE 35 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028) 132
  • FIGURE 36 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 134
  • FIGURE 37 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: SNAPSHOT (2019) 139
  • FIGURE 38 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY REGION (2019) 140
  • FIGURE 39 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY REGION (2021 & 2028) 140
  • FIGURE 40 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY REGION (2020 & 2028) 141
  • FIGURE 41 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DRUG TYPE (2021-2028) 141
  • FIGURE 42 NORTH-AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: SNAPSHOT (2020) 143
  • FIGURE 43 NORTH-AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2020) 144
  • FIGURE 44 NORTH-AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2021 & 2028) 144
  • FIGURE 45 NORTH-AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2021 & 2028) 145
  • FIGURE 46 NORTH-AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE (2021-2028) 145
  • FIGURE 47 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: SNAPSHOT (2020) 170
  • FIGURE 48 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2020) 171
  • FIGURE 49 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2021 & 2028) 171
  • FIGURE 50 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2021 & 2028) 172
  • FIGURE 51 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE (2021-2028) 172
  • FIGURE 52 ASIA-PACIFIC CANCER SUPPORTIVE CARE PRODUCTS MARKET: SNAPSHOT (2020) 234
  • FIGURE 53 ASIA-PACIFIC CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2020) 235
  • FIGURE 54 ASIA-PACIFIC CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2021 & 2028) 235
  • FIGURE 55 ASIA-PACIFIC CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2021 & 2028) 236
  • FIGURE 56 ASIA-PACIFIC CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE (2021-2028) 236
  • FIGURE 57 SOUTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: SNAPSHOT (2020) 304
  • FIGURE 58 SOUTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2020) 306
  • FIGURE 59 SOUTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2021 & 2028) 306
  • FIGURE 60 SOUTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2021 & 2028) 307
  • FIGURE 61 SOUTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE (2021-2028) 307
  • FIGURE 62 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: SNAPSHOT (2020)S 327
  • FIGURE 63 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2020) 328
  • FIGURE 64 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2021 & 2028) 328
  • FIGURE 65 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2021 & 2028) 329
  • FIGURE 66 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE (2021-2028) 329
  • FIGURE 67 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: COMPANY SHARE 2020 (%) 367
  • FIGURE 68 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: COMPANY SHARE 2020 (%) 368
  • FIGURE 69 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: COMPANY SHARE 2020 (%) 369
  • FIGURE 70 ASIA-PACIFIC CANCER SUPPORTIVE CARE PRODUCTS MARKET: COMPANY SHARE 2020 (%) 370
目次

Global cancer supportive care products market is projected to register a CAGR of 4.8% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.

Market Segmentation:

Global Cancer Supportive Care Products Market, By Drug Type (Granulocyte Colony Stimulating Factor (GCSFs), Erythropoietin Stimulating Agents (ESA'S), Opioid Analgesics, Monoclonal Antibodies, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Bisphosphonates, Anti-Emetics, Antihistamines and Others), Type (Branded and Generics), Cancer Type (Lung Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Bladder Cancer, Leukaemia, Melanoma, Ovarian Cancer and Other Cancers), End User (Hospitals, Clinics, Hospitals & Academic Institutions and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Compounding Pharmacies), Country (U.S., Canada, Mexico, U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey, Poland, rest of Europe, China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, rest of Asia-Pacific, South Africa, Oman, Saudi Arabia, U.A.E., Egypt, Israel and rest of Middle East and Africa, Brazil, Argentina and rest of South America) Industry Trends and Forecast to 2028

Some of the major factors contributing to the growth of global cancer supportive care products market are:

Growing cancer burden worldwide

Rising research and development activities in oncology sector

Market Players:

The key market players for global cancer supportive care products market are listed below:

Amgen Inc.

Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.)

Pfizer Inc.

APR

Novartis AG

F. Hoffmann-La Roche Ltd

Acacia Pharma Group Plc

Baxter

Bayer AG

Helsinn Healthcare SA

Heron Therapeutics, Inc.

Kyowa Kirin Co., Ltd.

Acrotech Biopharma

Spectrum Pharmaceuticals, Inc.

Oxford Pharmascience Ltd

Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.)

Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.)

Tersera Therapeutics LLC, Mylan N.V., Sun Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET
  • 1.4 CURRENCY AND PRICING
  • 1.5 LIMITATIONS
  • 1.6 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 DRUG TYPE LIFELINE CURVE
  • 2.8 DBMR MARKET POSITION GRID
  • 2.9 VENDOR SHARE ANALYSIS
  • 2.10 SECONDARY SOURCES
  • 2.11 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 REGULATORY

5 MARKET OVERVIEW

  • 5.1 DRIVERS
    • 5.1.1 GROWING CANCER BURDEN WORLDWIDE
    • 5.1.2 INCREASING INITIATIVES BY GOVERNMENT AND OTHER HEALTHCARE ORGANIZATIONS
    • 5.1.3 GROWING GERIATRIC POPULATION
    • 5.1.4 RISING NUMBER OF PRODUCT APPROVAL
    • 5.1.5 RISING EXPENDITURE ON HEALTHCARE
  • 5.2 RESTRAINTS
    • 5.2.1 ADVERSE EFFECTS AND RISKS ASSOCIATED WITH CANCER SUPPORTIVE DRUGS
    • 5.2.2 LACK OF EARLY DETECTION
  • 5.3 OPPORTUNITIES
    • 5.3.1 ACQUISITION AND AGREEMENT BY MAJOR PLAYERS
    • 5.3.2 RISING PRODUCT LAUNCHES
    • 5.3.3 GROWING R&D ACTIVITIES
  • 5.4 CHALLENGES
    • 5.4.1 STRINGENT REGULATION POLICY
    • 5.4.2 PATENT EXPIRY OF DRUGS

6 COVID-19 IMPACT ON GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET

  • 6.1 PRICE IMPACT
  • 6.2 IMPACT ON SUPPLY CHAIN
  • 6.3 IMPACT ON DEMAND
  • 6.4 STRATEGIC DECISIONS FOR MANUFACTURERS
  • 6.5 CONCLUSION

7 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE

  • 7.1 OVERVIEW
  • 7.2 GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS)
    • 7.2.1 LONG ACTING FILGRASTIM
    • 7.2.2 FILGRASTIM
    • 7.2.3 LENOGRASTIM
  • 7.3 ERYTHROPOIETIN STIMULATING AGENTS (ESA'S)
    • 7.3.1 EPO-A/B
    • 7.3.2 DPO
    • 7.3.3 CERA
    • 7.3.4 EPO-K
  • 7.4 OPIOID ANALGESICS
    • 7.4.1 FENTANYL
    • 7.4.2 METHADONE
    • 7.4.3 TRAMADOL
    • 7.4.4 OTHERS
  • 7.5 MONOCLONAL ANTIBODIES
  • 7.6 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
    • 7.6.1 OTC NSAIDS
      • 7.6.1.1 ASPIRIN
      • 7.6.1.2 IBUPROFEN
      • 7.6.1.3 NAPROXEN SODIUM
    • 7.6.2 PRESCRIPTION NSAIDS
      • 7.6.2.1 CELECOXIB
      • 7.6.2.2 DICLOFENAC
      • 7.6.2.3 INDOMETHACIN
      • 7.6.2.4 KETOROLAC
      • 7.6.2.5 MELOXICAM
      • 7.6.2.6 NABUMETONE
      • 7.6.2.7 NAPROXEN
      • 7.6.2.8 OXAPROZIN
      • 7.6.2.9 PIROXICAM
      • 7.6.2.10 SULINDAC
      • 7.6.2.11 OTHERS
  • 7.7 BISPHOSPHONATES
    • 7.7.1 ZOLEDRONIC ACID OR ZOLEDRONATE
    • 7.7.2 DISODIUM PAMIDRONATE
    • 7.7.3 IBANDRONIC ACID OR IBANDRONATE
    • 7.7.4 SODIUM CLODRONATE
  • 7.8 ANTI-EMETICS
    • 7.8.1 APREPITANT
    • 7.8.2 DEXAMETHASONE
    • 7.8.3 DOLASETRON
    • 7.8.4 GRANISETRON
    • 7.8.5 ONDANSETRON
    • 7.8.6 PALONOSETRON
    • 7.8.7 PROCHLORPERAZINE
    • 7.8.8 ROLAPITANT
    • 7.8.9 OTHERS
  • 7.9 ANTIHISTAMINES
    • 7.9.1 HYDROXYZINE
    • 7.9.2 DIPHENHYDRAMINE
    • 7.9.3 OTHERS
  • 7.10 OTHERS

8 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE

  • 8.1 OVERVIEW
  • 8.2 BRANDED
    • 8.2.1 NEULASTA
    • 8.2.2 ARANESP
    • 8.2.3 PROLIA
    • 8.2.4 XGEVA
    • 8.2.5 EPOGEN
    • 8.2.6 EPREX
    • 8.2.7 NEUPOGEN
    • 8.2.8 OTHERS
  • 8.3 GENERICS

9 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE

  • 9.1 OVERVIEW
  • 9.2 LUNG CANCER
  • 9.3 BREAST CANCER
  • 9.4 PROSTATE CANCER
  • 9.5 LIVER CANCER
  • 9.6 BLADDER CANCER
  • 9.7 LEUKAEMIA
  • 9.8 MELANOMA
  • 9.9 OVARIAN CANCER
  • 9.10 OTHER CANCERS

10 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER

  • 10.1 OVERVIEW
  • 10.2 HOSPITALS
    • 10.2.1 ACUTE CARE HOSPITALS
    • 10.2.2 LONG-TERM CARE HOSPITALS
    • 10.2.3 NURSING FACILITIES
  • 10.3 CLINICS
  • 10.4 HOSPITALS & ACADEMIC INSTITUTIONS
  • 10.5 OTHERS

11 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL

  • 11.1 OVERVIEW
  • 11.2 HOSPITAL PHARMACIES
  • 11.3 RETAIL PHARMACIES
  • 11.4 COMPOUNDING PHARMACIES

12 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY GEOGRAPHY

  • 12.1 OVERVIEW
  • 12.2 NORTH AMERICA
    • 12.2.1 U.S.
    • 12.2.2 CANADA
    • 12.2.3 MEXICO
  • 12.3 EUROPE
    • 12.3.1 GERMANY
    • 12.3.2 FRANCE
    • 12.3.3 U.K
    • 12.3.4 ITALY
    • 12.3.5 SPAIN
    • 12.3.6 SWITZERLAND
    • 12.3.7 NETHERLANDS
    • 12.3.8 RUSSIA
    • 12.3.9 TURKEY
    • 12.3.10 REST OF EUROPE
  • 12.4 ASIA-PACIFIC
    • 12.4.1 JAPAN
    • 12.4.2 CHINA
    • 12.4.3 INDIA
    • 12.4.4 SOUTH KOREA
    • 12.4.5 AUSTRALIA
    • 12.4.6 SINGAPORE
    • 12.4.7 MALAYSIA
    • 12.4.8 THAILAND
    • 12.4.9 INDONESIA
    • 12.4.10 PHILIPPINES
    • 12.4.11 REST OF ASIA-PACIFIC
  • 12.5 SOUTH AMERICA
    • 12.5.1 BRAZIL
    • 12.5.2 ARGENTINA
    • 12.5.3 REST OF SOUTH AMERICA
  • 12.6 MIDDLE EAST & AFRICA
    • 12.6.1 SOUTH AFRICA
    • 12.6.2 SAUDI ARABIA
    • 12.6.3 UAE
    • 12.6.4 ISRAEL
    • 12.6.5 EGYPT
    • 12.6.6 REST OF MIDDLE EAST AND AFRICA

13 GLOBAL CANCER SUPPORTIVE CARE PRODUCTS MARKET: COMPANY LANDSCAPE

  • 13.1 COMPANY SHARE ANALYSIS: GLOBAL
  • 13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
  • 13.3 COMPANY SHARE ANALYSIS: EUROPE
  • 13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

14 SWOT

15 COMPANY PROFILES

  • 15.1 AMGEN INC.
    • 15.1.1 COMPANY SNAPSHOT
    • 15.1.2 REVENUE ANALYSIS
    • 15.1.3 COMPANY SHARE ANALYSIS
    • 15.1.4 PRODUCT PORTFOLIO
    • 15.1.5 RECENT DEVELOPMENTS
  • 15.2 PFIZER INC.
    • 15.2.1 COMPANY SNAPSHOT
    • 15.2.2 REVENUE ANALYSIS
    • 15.2.3 COMPANY SHARE ANALYSIS
    • 15.2.4 PRODUCT PORTFOLIO
    • 15.2.5 RECENT DEVELOPMENTS
  • 15.3 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
    • 15.3.1 COMPANY SNAPSHOT
    • 15.3.2 REVENUE ANALYSIS
    • 15.3.3 COMPANY SHARE ANALYSIS
    • 15.3.4 PRODUCT PORTFOLIO
    • 15.3.5 RECENT DEVELOPMENTS
  • 15.4 NOVARTIS AG
    • 15.4.1 COMPANY SNAPSHOT
    • 15.4.2 REVENUE ANALYSIS
    • 15.4.3 COMPANY SHARE ANALYSIS
    • 15.4.4 PRODUCT PORTFOLIO
    • 15.4.5 RECENT DEVELOPMENTS
  • 15.5 ACACIA PHARMA GROUP PLC
    • 15.5.1 COMPANY SNAPSHOT
    • 15.5.2 PRODUCT PORTFOLIO
    • 15.5.3 RECENT DEVELOPMENTS
  • 15.6 ACROTECH BIOPHARMA
    • 15.6.1 COMPANY SNAPSHOT
    • 15.6.2 PRODUCT PORTFOLIO
    • 15.6.3 RECENT DEVELOPMENT
  • 15.7 APR
    • 15.7.1 COMPANY SNAPSHOT
    • 15.7.2 PRODUCT PORTFOLIO
    • 15.7.3 RECENT DEVELOPMENTS
  • 15.8 BAXTER
    • 15.8.1 COMPANY SNAPSHOT
    • 15.8.2 REVENUE ANALYSIS
    • 15.8.3 PRODUCT PORTFOLIO
    • 15.8.4 RECENT DEVELOPMENT
  • 15.9 BAYER AG
    • 15.9.1 COMPANY SNAPSHOT
    • 15.9.2 REVENUE ANALYSIS
    • 15.9.3 PRODUCT PORTFOLIO
    • 15.9.4 RECENT DEVELOPMENTS
  • 15.10 F. HOFFMANN-LA ROCHE LTD
    • 15.10.1 COMPANY SNAPSHOT
    • 15.10.2 REVENUE ANALYSIS
    • 15.10.3 PRODUCT PORTFOLIO
    • 15.10.4 RECENT DEVELOPMENTS
  • 15.11 HELSINN HEALTHCARE SA
    • 15.11.1 COMPANY SNAPSHOT
    • 15.11.2 PRODUCT PORTFOLIO
    • 15.11.3 RECENT DEVELOPMENTS
  • 15.12 HERON THERAPEUTICS, INC.
    • 15.12.1 COMPANY SNAPSHOT
    • 15.12.2 REVENUE ANALYSIS
    • 15.12.3 PRODUCT PORTFOLIO
    • 15.12.4 RECENT DEVELOPMENTS
  • 15.13 KYOWA KIRIN CO., LTD.
    • 15.13.1 COMPANY SNAPSHOT
    • 15.13.2 REVENUE ANALYSIS
    • 15.13.3 PRODUCT PORTFOLIO
    • 15.13.4 RECENT DEVELOPMENTS
  • 15.14 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
    • 15.14.1 COMPANY SNAPSHOT
    • 15.14.2 REVENUE ANALYSIS
    • 15.14.3 PRODUCT PORTFOLIO
    • 15.14.4 RECENT DEVELOPMENTS
  • 15.15 MYLAN N.V.
    • 15.15.1 COMPANY SNAPSHOT
    • 15.15.2 REVENUE ANALYSIS
    • 15.15.3 PRODUCT PORTFOLIO
    • 15.15.4 RECENT DEVELOPMENTS
  • 15.16 OXFORD PHARMASCIENCE LTD
    • 15.16.1 COMPANY SNAPSHOT
    • 15.16.2 TECHNOLOGY PORTFOLIO
    • 15.16.3 RECENT DEVELOPMENT
  • 15.17 SPECTRUM PHARMACEUTICALS, INC.
    • 15.17.1 COMPANY SNAPSHOT
    • 15.17.2 REVENUE ANALYSIS
    • 15.17.3 PRODUCT PORTFOLIO
    • 15.17.4 RECENT DEVELOPMENT
  • 15.18 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • 15.18.1 COMPANY SNAPSHOT
    • 15.18.2 REVENUE ANALYSIS
    • 15.18.3 PRODUCT PORTFOLIO
    • 15.18.4 RECENT DEVELOPMENTS
  • 15.19 TERSERA THERAPEUTICS LLC
    • 15.19.1 COMPANY SNAPSHOT
    • 15.19.2 PRODUCT PORTFOLIO
    • 15.19.3 RECENT DEVELOPMENT
  • 15.20 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
    • 15.20.1 COMPANY SNAPSHOT
    • 15.20.2 REVENUE ANALYSIS
    • 15.20.3 PRODUCT PORTFOLIO
    • 15.20.4 RECENT DEVELOPMENTS

16 QUESTIONNAIRE

17 RELATED REPORTS